Although payer decision-making has been a key use of real-world evidence (RWE) and real-world data (RWD) in the healthcare space, there are far more avenues in which these resources can advance medicine. Agencies like the US Food and Drug Administration (FDA) are increasingly using RWE and RWD to make regulatory decisions, while market access teams implement strategies based on the perspectives they inform.
Regulatory Scientific and Health Solutions (R-S-S) is hosting a course entitled, “Economic Evaluation of Cancer Drugs.” The course is aimed towards professionals in health economics and outcomes research (HEOR), market access, and clinical oncology. Attendees will learn about the development, application, and interpretation of economic models for cancer drugs. The course takes place at the Hilton London Watford, Watford, UK on Monday 3rd October 2022. Register by 1st August 2022 for an early bird discount.